Amedisys Inc. (AMED) Sees Large Volume Increase
Amedisys Inc. (NASDAQ:AMED) saw unusually-high trading volume on Wednesday . Approximately 1,273,037 shares traded hands during trading, an increase of 372% from the previous session’s volume of 269,557 shares.The stock last traded at $50.72 and had previously closed at $53.78.
AMED has been the topic of several analyst reports. Oppenheimer Holdings Inc. restated a “buy” rating and set a $56.00 price objective on shares of Amedisys in a report on Wednesday, May 4th. Mizuho restated a “buy” rating and set a $57.00 price objective (up from $49.00) on shares of Amedisys in a report on Monday, April 11th. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $57.00 price objective on the stock in a report on Monday, May 9th. Jefferies Group restated a “buy” rating and set a $59.00 price objective on shares of Amedisys in a report on Wednesday, May 25th. Finally, Stephens initiated coverage on Amedisys in a report on Thursday, June 16th. They set an “equal weight” rating and a $55.00 price objective on the stock. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $51.75.
The stock’s 50-day moving average price is $51.45 and its 200-day moving average price is $46.43. The company has a market capitalization of $1.71 billion and a price-to-earnings ratio of 44.23.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported $0.42 EPS for the quarter, meeting the consensus estimate of $0.42. The firm earned $360 million during the quarter, compared to analyst estimates of $353.07 million. The company’s revenue was up 14.8% on a year-over-year basis. During the same period last year, the company earned $0.43 EPS. Equities research analysts forecast that Amedisys Inc. will post $1.74 earnings per share for the current fiscal year.
In other news, insider Scott G. Ginn sold 6,000 shares of the stock in a transaction that occurred on Wednesday, May 11th. The stock was sold at an average price of $51.62, for a total value of $309,720.00. Following the completion of the transaction, the insider now directly owns 48,009 shares of the company’s stock, valued at approximately $2,478,224.58. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bruce D. Perkins bought 1,000 shares of the company’s stock in a transaction dated Friday, May 13th. The stock was bought at an average cost of $50.21 per share, with a total value of $50,210.00. Following the completion of the acquisition, the director now owns 10,354 shares in the company, valued at approximately $519,874.34. The disclosure for this purchase can be found here.
Several institutional investors recently modified their holdings of the company. Trexquant Investment LP bought a new position in shares of Amedisys during the fourth quarter worth about $1,031,000. Cornerstone Capital Management Holdings LLC. boosted its stake in Amedisys by 230.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 31,100 shares of the company’s stock worth $1,223,000 after buying an additional 21,700 shares in the last quarter. Rhumbline Advisers boosted its stake in Amedisys by 5.3% in the fourth quarter. Rhumbline Advisers now owns 37,499 shares of the company’s stock worth $1,474,000 after buying an additional 1,875 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Amedisys by 20.3% in the fourth quarter. GSA Capital Partners LLP now owns 38,192 shares of the company’s stock worth $1,502,000 after buying an additional 6,437 shares in the last quarter. Finally, Sei Investments Co. boosted its stake in Amedisys by 1,922,350.0% in the fourth quarter. Sei Investments Co. now owns 38,449 shares of the company’s stock worth $1,512,000 after buying an additional 38,447 shares in the last quarter.
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.